Mirati Therapeutics - European Commission Approves KRAZATI a

Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation

Switzerland - Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced that the European Commission granted conditional marketing authorization for KRAZATI as a...

Related Keywords

Switzerland , Liechtenstein , Norway , Germany , Grosshansdorf , Schleswig Holstein , Iceland , Martin Reck , Charles Baum , European Commission , Exchange Commission , European Union , Union Register , Committee For Medicinal Products Human Use , European Medicines Agency , Nasdaq , Mirati Therapeutics Inc , Lung Clinic , Medicinal Products , Human Use , Product Characteristics , Medicines Agency , News Publishing , Markets ,